glp-1 agonist dpp 4 inhibitor Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Renoprotective effects of incretin‐based drugs:

The hydroxyl radical induces the formation of DNA-protein cross-links, single- and double-stranded breaks, lipid peroxidation, and protein fragmentation

Medicines known as GLP-1 receptor agonists imitate the actions of this hormone

PMID: 36615738

Pinzani M, and K Rombouts (2004) Liver Fibrosis: From the Bench to Clinical Targets

Maintenance dosing is required every 714 days to prevent melanocyte activity from returning to baseline

Spending on glucagon-like peptide-1 receptor agonists among US adults, JAMA Network Open (2025) H.R.4818 treat and reduce obesity act of 2023, Congress.gov (2023) Anti-obesity drugs will not be covered by Medicare and Medicaid in 2026, American College of Gastroenterology (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice